Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMSB0J8)

Drug Name
L-734217 Drug Info
Synonyms
L-734217; UNII-3JRV8H947H; CHEMBL48371; 3JRV8H947H; 146144-48-1; AC1L42ZO; L 734217; SCHEMBL6886518; L-734,217; CTK4C4832; Butanoic acid,3-[[2-[(3R)-2-oxo-3-[2-(4-piperidinyl)ethyl]-1-piperidinyl]acetyl]amino]-,(3R)-; BDBM50033030; AKOS030571127; 3-{2-[2-Oxo-3-(2-piperidin-4-yl-ethyl)-piperidin-1-yl]-acetylamino}-butyric acid (L-734217); (R)-3-{2-[(R)-2-Oxo-3-(2-piperidin-4-yl-ethyl)-piperidin-1-yl]-acetylamino}-butyric acid; (3R)-3-[[2-[(3R)-2-oxo-3-(2-piperidin-4-ylethyl)piperidin-1-yl]acetyl]amino]butanoic acid
Indication
Disease Entry ICD 11 Status REF
Thrombosis DB61-GB90 Discontinued in Phase 1 [1]
Cross-matching ID
PubChem CID
177831
CAS Number
CAS 146144-48-1
TTD Drug ID
DMSB0J8

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Download the Complete Related Drug List
Drug(s) Targeting Glycoprotein IIb/IIIa receptor (GPIIb/IIIa)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Hydroquinone DM6AVR4 Melasma ED60.1 Approved [3]
Eptifibatide DMQXTJS Acute cardiac ischemic events BA40.Z Approved [4]
Tirofiban DMQG17S Acute coronary syndrome BA41 Approved [5]
Abciximab DMJO6GV Acute disease Approved [5]
DMP-444 DMO7BQS Coronary artery disease BA80 Phase 3 [6]
99mTc-rBitistatin DMFAMNH Pulmonary embolism JB42 Phase 1/2 [7]
AjvW2 DM6PN4H Thrombosis DB61-GB90 Phase 1 [8]
SDZ-GPI-562 DMU9ZGN Thrombosis DB61-GB90 Phase 1 [9]
RGD-891 DMVJMF1 Thrombosis DB61-GB90 Phase 1 [10]
Lefradafiban DMKZVLH Angina pectoris BA40 Phase 1 [11]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Glycoprotein IIb/IIIa receptor (GPIIb/IIIa) TT38RM1 ITA2B_HUMAN; ITB3_HUMAN Modulator [2]

References

1 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800006092)
2 Nonpeptide glycoprotein IIb/IIIa inhibitors. 8. Antiplatelet activity and oral antithrombotic efficacy of L-734,217. J Pharmacol Exp Ther. 1996 Jul;278(1):62-73.
3 Accutin, a new disintegrin, inhibits angiogenesis in vitro and in vivo by acting as integrin alphavbeta3 antagonist and inducing apoptosis. Blood. 1998 Nov 1;92(9):3268-76.
4 Barbourin. A GPIIb-IIIa-specific integrin antagonist from the venom of Sistrurus m. barbouri. J Biol Chem. 1991 May 25;266(15):9359-62.
5 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
6 Evaluation of Tc-99m-labeled glycoprotein IIb/IIIa receptor antagonist DMP444 SPECT in patients with infective endocarditis. Clin Nucl Med. 2003 Jun;28(6):480-4.
7 Platelet binding and biodistribution of [99mTc]rBitistatin in animal species and humans. Nucl Med Biol. 2007 Oct;34(7):855-63.
8 Novel approaches to the treatment of thrombosis. Trends Pharmacol Sci. 2002 Jan;23(1):25-32.
9 Heparin-induced thrombocytopenia: the role of platelet activation and therapeutic implications. Semin Thromb Hemost. 1999;25 Suppl 1:67-75.
10 Pharmacokinetics, pharmacodynamics, and safety of a platelet GPIIb/IIIa antagonist, RGD891, following intravenous administration in healthy male volunteers. J Clin Pharmacol. 2000 Nov;40(11):1245-56.
11 Pharmacodynamics and safety of lefradafiban, an oral platelet glycoprotein IIb/IIIa receptor antagonist, in patients with stable coronary artery disease undergoing elective angioplasty. Heart. 2001 Apr;85(4):444-50.